Advertisement

Topics

EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?

03:40 EDT 14 Jun 2019 | ecancermedicalscience

Acute myeloid leukaemia (AML) is a rare, highly fatal blood cancer. Allogeneic haematopoietic cell transplantation (Allo-HCT, also known as “bone marrow transplant”) is a curative therapy in some, but not all, AML patients after initial...

Original Article: EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?

NEXT ARTICLE

More From BioPortfolio on "EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...